55 results about "Liver weight" patented technology

The invention provides a micropterus salmoides mixed feed with yeast hydrolysate replacing fish meal. The micropterus salmoides mixed feed comprises 15-22 percent of the fish meal, 10-15 percent of pea protein powder, 10-15 percent of bean pulp, 1-5 percent of krill powder, 10-15 percent of gluten, 1-5 percent of phospholipid, 5-10 percent of fish oil, 1-5 percent of premix, 15-25 percent of flour, 1-5 percent of wheat middling, 0.5-3 percent of lysine, 0.1-1 percent of methionine, 0.1-1 percent of threonine and 1-8 percent of the yeast hydrolysate. The use amount of the fish meal is decreased, the cost is reduced, and the economic benefit of a farmer is increased; in addition, the ratio of liver weight and body weight can be reduced, and the intestinal and liver functions of micropterus salmoides are improved.

The invention discloses functions and use of zinc finger protein A20 in treating fatty liver and type 2 diabetes mellitus, and belongs to the fields of the functions and the uses of genes. The functions of the A20 are studied by use of high fat diet-induced models; results indicate that the body weight and the fasting blood glucose level of A20 knockout mice in an HFD (High Fat Diet) group both are higher than those of WT mice in a control group; intraperitoneal injection glucose tolerance experiments show that the tolerance ability of the A20 knockout mice to the glucose is obviously weakened; the general liver appearance, the liver weight, the liver / weight ratio, the lipid component pathological staining result and the like of the mice all indicate that the fatty liver lesion of the A20-KO mice in the HFD group is obviously deteriorated and the lipid accumulation is remarkably increased, and the results indicate that the fatty liver and the type 2 diabetes mellitus can be remarkably worsened due to A20 knockout. For the effects of the A20, the A20 can be applied to preparing medicines for preventing, relieving and / or treating the fatty liver and / or the type 2 diabetes mellitus.

The present invention relates to a feed capable of promoting goose growth, making its body be stout and strong and increasing goose liver weight. Said feed is made up by using (by wt%) 96.8375%-98.374% of corn, 0.5%-1.0% of edible salt, 1.0%-2.0% of vegetable oil, 0.015%-0.025% of composite enzyme, 0.008%-0.01% of phytase, 0.1%-0.12% of probiotics preparation and 0.003%-0.0075% of xanthophylls as raw material through a certain preparation process.

The invention discloses an application of a fly maggot powder for the health-care functions of anti-fatigue, anti-aging and anti-obesity. The fly maggot powder is used for producing health care products of anti-fatigue, anti-aging and anti-obesity. Five percent of fly maggot powder is added into the feed for feeding the strain of D-galactose-induced aging C57BL / 6 rat to test and find that the fly maggot powder has remarkable effect in anti-fatigue; in a rat model induced by combined biological rhythm disorder and the D-galactose, the fly maggot powder can effectively prevent the reduction of liver weight, the descending of the activity and the corresponding gene expression of superoxide dismutase, glutathione peroxidase, catalase and other antioxidases, and the increase of the content of MDA of the products of lipid peroxidation caused by aging. The fly maggot powder has remarkable efficacy of anti-aging; 5 percent of the fly maggot powder is added in the high-fat feed, which can effectively prevent the rapid growth of Wistar rats as a result of high-fat diet and can suggests that the fly maggot powder has remarkable effect of anti-obesity.

The invention discloses application of antrodia cinnamomea and monomer lanostane 32 in preventing and treating non-alcoholic fatty liver. The novel specific application of the antrodia cinnamomea and the monomer lanostane 32, provided by the invention, is application of the antrodia cinnamomea, a fruiting body extract of the antrodia cinnamomea, a monomeric compound obtained by separation from the fruiting body extract of the antrodia cinnamomea, the lanostane 32 or a substance containing all the above materials in a product for treating and / or preventing the non-alcoholic fatty liver. Experiments prove that by using the antrodia cinnamomea and the monomer lanostane 32, the deposit rate of lipid in liver of a sicken body with the non-alcoholic fatty liver is reduced, the content of total triglyceride is reduced, expression levels of inflammatory factors and fibrosis related factors are reduced, the content of 4-hydroxynonenal in serum is reduced, as well as deposition of the lipid in the body liver caused by the non-alcoholic fatty liver, and increase of body weight and liver weight also can be prevented. Therefore, the antrodia cinnamomea and the monomer lanostane 32 have important effects on preventing and treating the non-alcoholic fatty liver.

The invention discloses application of a baicalein extract in preparation of a medicament for controlling hyperlipidemic fatty liver. The baicalein extract is proved to have effect of preventing the hyperlipidemic fatty liver in pharmacological experiments, and is particularly used for reducing the liver weight and the liver coefficient of rats and reducing the content of the blood fat and liver lipid.

The invention discloses goose feed with folium mori powder.The goose feed comprises, by weight, 59.00% of second-grade corn, 20.15-21.00% of second-grade bean pulp, 10.42-10.53% of second-grade paddy, 3.00-4.21% of rice husk, 2.00-4.00% of the folium mori powder, 1.00% of 1% meat goose compound premixes, 1.00% of dicalcium phosphate, 0.15-0.20% of lysine 98, 0.20-0.22% of salt and 1.00% of stone powder.The goose feed with the folium mori powder has the advantages that the meat goose slaughter rate can be obviously increased, the liver weights can be obviously increased, development of liver functions can be promoted, fat goose livers can be produced, accordingly, an economical benefit can be increased, and suffering and harm to existing geese due to the fact that fat goose livers of the existing geese are produced by means of forced feeding can be prevented; digestive absorption of fat in the feed can be promoted for meat geese, blood lipid can be lowered, deposition of tissue cholesterol can be reduced, blood glucose can be lowered, health conditions of the geese can be improved, and the quality of goose meat and the goose livers can be improved.

The invention relates to a feed additive for increasing geese liver weight and content of unsaturated fatty acids, belonging to the technology field of livestock production, which is a novel feed additive for increasing geese liver weight and content of unsaturated fatty acids. The feed additive comprises vitamin C 50-200 g, vitamin E 6-7.2 g, Euthyrox 1.5-2 g, and pharmaceutical starch or glucose as adjuvant 800-938 g. The feed additive has prominent effect in increasing liver weight and content of unsaturated fatty acids; and the geese liver weight is increased by 39.45%, the content of abdominal fats is decreased by 0.1%, and the content of unsaturated fatty acids is increased by 4.6%. The feed additive has the advantages of high efficiency, low toxicity, low drug residues, fulfillment of environmental friendliness requirement for meat products, good safety, and low cost. The feed additive can also enhance immunity of geese, and can be stored at room temperature in a dark, sealed and moisture-proof environment for 3 years.

The invention aims to provide a high-efficiency plant compound protein. The high-efficiency plant compound protein is prepared from the following components in parts: 4.85 to 5.41 parts of peanut meal, 8.92 to 9.81 parts of corn protein powder, 8.18 to 8.99 parts of soya bean meal, 2.37 to 2.72 parts of wheat gluten and 10.93 to 12.04 parts of cottonseed meal. The plant compound protein is used for replacing fish meal to prepare a scophthalmus maximus feed. The plant compound protein provided by the invention can effectively replace 70 percent of fish meal protein in an all-fish meal feed of the scophthalmus maximus feed; the final body weight, the specific growth rate, the survival rate, the fatness, the ratio of liver weight to body weight and the ratio of viscera weight to body weight of scophthalmus maximus are not influenced; the body compositions of a conventional body of the scophthalmus maximus are not influenced; the digestion rate of dry matters and proteins of the feed is not influenced; various indexes in serum are not influenced. The purposes of reducing feed cost and reducing cultivation cost are achieved, and theoretical basis is provided for sustainable development of aquaculture.

The invention discloses application of a fructus schisandrae sphenantherae extract in preparation of a liver regeneration medicine. The fructus schisandrae sphenantherae extract is an alcohol extract of dried fruits of schisandrae sphenantherae, and the main effective ingredients of the fructus schisandrae sphenantherae extract comprise schisantherin and deoxyschizandrin. A partial hepatectomy mouse model is utilized, the fructus schisandrae sphenantherae extract is cooperatively applied, a result shows that the fructus schisandrae sphenantherae extract has the characteristics of being capable of significantly improving the quick recovering capacity of the liver-weight ratio and improving the quick proliferation capacity of liver cells, the mechanism relates to significant activation of protein expression of a related cell cycle, the manifestation is that cyclin D1 and PCNA proteins are significantly up-regulated, and meanwhile obvious improvement on liver tissue inflammatory infiltration and liver cell swelling is achieved. Experimental results show that the fructus schisandrae sphenantherae extract supplies a novel method and treatment means to liver regeneration after hepatectomy.

The invention discloses a traditional Chinese medicine composition for treating simple obesity, and a preparation method and an application thereof. The traditional Chinese medicine composition is prepared by using 5-30 parts by mass of white atractylodes rhizome, 10-30 parts by mass of fried turtle shell, 10-20 parts by mass of inula flowers, 10-20 parts by mass of curcuma zedoary and 10-20 parts by mass of giant knotweed rhizome as raw materials. Specifically, the preparation method comprises the following steps of weighing all medicines according to the above proportions; smashing the fried turtle shell; adding water 10 times by volume that of the fried turtle shell; decocting for 30 minutes; adding traditional Chinese medicinal materials; adding water and decocting for two times, wherein the volume of added water in each time is 8-10 times that of a total mass of the medicines; and the time for each decoction is 0.5-1 hour; merging extract solutions obtained by the two times of decoction; filtering, concentrating, and drying to obtain a dry extract. Animal experiments show that the composition can significantly reduce body weight, liver weight and fat weight of high-fat obese rats, significantly reduce the contents of liver cholesterol and liver triglyceride in the high-fat obese rats, regulate lipid metabolism and improve liver functions. The medicine effects are related to the fact that the composition can increase bile flow, regulate and increase bile acid subfractions that can promote bile secretion and the lipid metabolism.

The invention belongs to the foodstuff and health product field, in particular relates to an application of the traditional Chinese medicine of medlar and blackfungus to the preparation of a drug for curing fatty liver. The invention adopts a medlar and blackfungus compound granular formulation. The fat emulsion made of fat, cholesterin, sodium taurocholate and propylthiouracil is given to rats; a fatty liver animal model is made; the function for preventing fatty liver of medlar and blackfungus is studied. The experimental results show that the medlar and the blackfungus have evident functions for preventing fatty liver and can reduce the liver weight / body mass index, the contents of serum and hepatic tissue cholesterin are decreased and the number of liver cells of steatosis is reduced. The medlar and the blackfungus can be used for preparing the drug for curing fatty liver.

The invention discloses functions and application of TNF (tumor necrosis factor) receptor associated factor 5 (TRAF5) in treatment of fatty liver and type 2 diabetes mellitus. Studies on a TRAF 5 gene by a high-fat diet (HFD) induced model discover that both the body weight and fasting plasma glucose level of an HFD bred TRAF gene knock-out mouse are lower than those of a WT mouse; glucose tolerance tests by intraperitoneal injection discover that the glucose tolerance of the TRAF5 gene knock-out mouse is remarkably reinforced; results of on liver gross appearance, liver weight, liver / body weight ratio and lipid component pathological staining indicate that the TRAF5-KO mouse fatty liver lesion in the HFD group is remarkably improved, the lipid accumulation is remarkably reduced, and the TRAF5 gene knock-out has the effects of remarkably improving fatty acid and type-II diabetes mellitus. Against the effects, the TRAF5 gene knock-out can be used as a medicinal target for screening and treating fatty liver and / or type-II diabetes mellitus, and the inhibitor of the TRAF5 gene knock-out can be used for preparing medicaments for treating fatty liver and / or type-II diabetes mellitus.

The present invention relates to a composition useful in the prevention and treatment of non-alcoholic fatty liver diseases caused by fat accumulated in the liver due to excessive nutrient ingestion or metabolic syndrome, regardless of alcohol consumption. The composition of the present invention can significantly improve the increased liver weight, accumulated liver triglycerides, increased serum ALT level, reduced liver SOD activity, and reduced liver total antioxidative capacity in experimental animals raised with a high-fat diet for a long period of time. Since the fatty liver diseases induced by the high-fat diet in the experimental animals shows similar pathological and immunological findings to human non-alcoholic fatty liver diseases, the composition of the present invention can be provided as an excellent pharmaceutical preparation or health supplement food used in the prevention and treatment of non-alcoholic fatty liver diseases.

The present invention is intended to provide a composition for preventing or improving metabolic syndrome, which is safe and efficiently ingestible. Provided is a composition for reducing blood cholesterol level, improving blood HDL / LDL cholesterol ratio, reducing blood triglyceride level, reducing blood sugar level, controlling increase in liver weight, and / or reducing body weight, the composition containing soybean germ protein as an active ingredient. The composition according to the present invention improves blood cholesterol level, triglyceride, and glucose levels thereby contributing to health promotion.

The invention relates to the technical field of healthcare food and medicine, and discloses new application of chrysanthemum extract. In the invention, the influence of the chrysanthemum extract on the blood fat and liver fat of mice is detected by detecting the influence of the chrysanthemum extract on the TC, TG and HDL-C content and liver weight coefficient in mouse blood and on the TC, TG, SOD and MDA content in the mouse liver tissue. The result indicates that the chrysanthemum extract has an effect of reducing blood fat as well as liver fat. Thus, the invention provides application of the chrysanthemum extract in preparing healthcare food and medicine for preventing and treating fatty liver.

The present invention describes a method to reduce blood aspartate transaminase level, liver weight, hepatic lipid accumulation and hepatocyte hypertrophy by administering the probiotic bacterium Parabacteroides goldsteinii to a subject showing signs of fatty liver disease. This probiotic bacterium can therefore be used to treat fatty liver disease.

The invention provides a technology for preparing a nutritional foie gras abundantly containing functional factors, belonging to the technical field of food science. The technology comprises the following steps: taking goose fat livers as raw materials and carrying out processing to prepare the nutritional foie gras abundantly containing functional factors. The invention is main characterized by comprising the following steps: adopting slow thaw at low temperature, washing with ice water mixture and stirring for four times; and adding 0.02%-0.1% of mixed functional nutrition ingredients (actively instant full-bone composite and selenium-polysaccharide), 3-5% of salts, 2-4% of white granulated sugars, 5-7% of five spice powders, 1-3% of chicken powders, 5-8% of green onions, 5-8% of fingers, 1-3% of sesame oils, 0.1-2% of emulsifiers, 0.1-5% of thickeners and a proper amount of water, wherein the water is the purified water and all ingredients are calculated based on a percentage of goose liver weight. The nutritional foie gras abundantly containing functional factors obtained by processing through the method has good quality, pure white color and luster, good taste, qualified sense, rationalization and safety and health quality.

The present invention provides a method to prepare polysaccharides from Ganoderma lucidum. The prepared polysaccharides can reduce liver weight and liver lipid content in humans and animals. The prepared polysaccharides can therefore be used to prevent and treat fatty liver disease.

The invention discloses functions and application of an LILRB4 (leukocyte immunoglobulin-like receptor B4) gene to treatment on fatty liver diseases and diabetes. By taking LILRB4 gene knock-out mice and wide type C57 mice as experimental subjects and through high fat diet (HFD) induced obesity mouse models, result shows that compared with the wild type (WT) C57 mice, the weight of the LILRB4-KO mice is not remarkably changed after HFD, but the fasting blood-glucose level of the LILRB4-KO mice is higher than that of the WT mice in the control group and the liver function of the LILRB4-KO mice is remarkably worse than that of the WT mice. Intraperitoneal injection glucose tolerance experiments show that the glucose tolerance of the LILRB4-KO mice is remarkably weakened. The liver weight and liver / weight ratio, the lipid component pathological staining result and the like indicate that the fatty liver lesion of the LILRB4-KO mice in the HFD group is remarkably deteriorated and the lipid accumulation is remarkably increased. Therefore, the LILRB4 can serve as a target for screening medicines for treating the fatty liver and / or the type 2 diabetes mellitus, and an accelerant of the LILRB4 can be used for preparing the medicines for treating the fatty liver and / or the type 2 diabetes mellitus.

The invention discloses a method for cultivating a raw duck for making a pressed salted duck. The method includes newly-hatched duckling brooding and adult duck filling, wherein the time for the adult duck filling is three weeks, and feeds for the adult duck filling are corn flour. The manufacturing method is as follows: cooking the corn flour thoroughly, twisting and pinching the corn flour into column-shaped bodies with the length of 4cm-6cm and the diameter of 1cm-1.5cm, the two ends of the column-shaped bodies are blunt, and the column-shaped bodies are called 'small pieces' in the following introduction. The method for adult duck filling is as follows: opening the duck mouth, pressing the duck tongue, filling the 'small pieces' into the duck mouth after the 'small pieces' are dipped with water for lubrication, and squeezing the 'small pieces' into the crop of the duck along the duck neck after one 'small piece' is filled. The raw duck cultivated through the cultivation method is plump and rich in elasticity, subcutaneous fat is thickened, and in addition, the tail portion is plump, and pectorals are full; full eviscerated dressing percentages are high; full eviscerated dressing percentages of drakes can reach 78.67%, and full eviscerated dressing percentages of female ducks can reach 77.34%; liver weight is increased obviously; and the average liver weight is 324.35 grams, and the maximum weight is 545 grams.

The invention relates to a Chinese herb medicinal additive for preventing tilapia fatty liver disease. The Chinese herb medicinal additive is characterized by comprising the following components in part by weight: 8 to 10 parts of mung bean, 1 to 3 parts of liquoric root, 1 to 3 parts of gentian, 1 to 3 parts of raw gardenia, 1 to 3 parts of baical skullcap root, 1 to 3 parts of bupleurum, 2 to 5parts of rehmannia root, 1 to 3 parts of plantain herb, 1 to 3 parts of virgate wormwood herb, 1 to 3 parts of indigowoad root, 1 to 3 parts of Mongolian dandelion herb, 2 to 5 parts of feverfew, 1 to 3 parts of turmeric root-tuber and 1 to 3 parts of oriental waterplantain rhizome. The Chinese herb medicinal additive has the advantages of capacities of obviously reducing liver weight / body weightand fat content of muscle and liver of the tilapia, reducing glutamic-oxalacetic transaminase activity, glutamic-pyruvic transaminase activity, total cholesterol content and triglycercide content in tilapia serum, protecting liver cells from the damage of factors such as nutritional factors, environmental factors and the like and effectively preventing nutritional fatty liver disease in the breeding process of the tilapia, convenient addition and use, capacity of being added in a commercial feed directly, synergistic effect of the components and other additive components in the commercial feed, improvement on the disease resistance of the tilapia, stable raw material source, low cost, simple production process and easy industrialized production.

The invention provides an application of diethyl n-butylmalonate in preparation of medicines for preventing and treating obesity, and belongs to the technical field of biomedicines. Diethyl n-butylmalonate can reduce body weight and liver weight in obese mice, prevent lipid accumulation in liver tissues, enhance fatty acid oxidation in obese mice and increase energy consumption so as to achieve weight losing effect. Moreover, Diethyl n-butylmalonate can improve glucose tolerance and insulin resistance, and has the effect of correcting obesity-related metabolic disorders.

A composition includes a black chokeberry extract and at least one of a thistle extract, a black hoof mushroom extract and a mixture thereof. The composition is effective in preventing and treating non-alcoholic fatty liver disease caused by accumulation of fat in the liver due to excessive intake of nutrients or metabolic syndrome regardless of alcohol intake. The composition can improve the increase in liver weight, accumulation of neutral fat in the liver, increase in serum ALT concentration, and reduction of liver SOD activity and total antioxidant activity of the liver, in experimental animals grown with a high-fat diet. Since the fatty liver disease caused by a high-fat diet in experimental animals shows similar pathological and immunological manifestations to human non-alcoholic fatty liver disease, the composition can be provided as a pharmaceutical agent or health supplement food used to prevent and treat non-alcoholic fatty liver disease.

The invention discloses the function and application of three-structural-domain protein 8 in treating non-alcoholic fatty liver disease and II type diabetes mellitus. TRIM8 gene knockout mice and wild type C57 mice are used as experimental subjects, by means of a high-fat diet induced fat mice model, the result indicates that compared with the wild type C57 mice, the weight of the TRIM8 gene knockout mice is reduced, the fasting blood-glucose level of the TRIM8 gene knockout mice is lower than that of control group WT mice, and hepatosis is obviously relieved. Mouse liver weight, the liver / weight ratio and a lipid component pathological staining result show that fatty liver pathological changes of the TRIM8-KO mice having high-fat diet are obviously relieved, and lipid accumulation is remarkably reduced. Therefore, TRIM8 can serve as a drug target for screening and treating fatty liver disease and / or II type diabetes mellitus, and inhibitor of TRIM8 can be used for preparing a drug for treating fatty liver disease and / or II type diabetes mellitus.

The invention provides a method for improving poultry production efficiency by rapidly evaluating liver weight and liver-to-body ratio, which comprises the following steps: (1) acquiring total cholesterol content in blood of a plurality of poultry in a preset poultry species group, and weighing the weight and liver weight of the plurality of poultry in the preset poultry species group through a balance; (2) respectively carrying out curve fitting on the obtained total cholesterol content, the liver weight and the liver-to-body ratio, and establishing a regression equation; (3) obtaining the total cholesterol content of the blood of the poultry to be detected in the preset poultry species group; and (4) obtaining the liver weight and the liver-to-body ratio of the poultry to be detected according to the regression method.

The invention discloses a function and application of thymidylate synthetase CAD (carbamoyl-phosphate synthetase II, aspartate transcarbamylase and dihydroorotase) genes in treating fatty liver and type-II diabetes mellitus, and belongs to the field of gene functions and application. Functions of CAD genes are studied by a high-fat diet (HFD) induced model, and results discover that the levels of body weight and fasting blood-glucose of a CAD gene knock-out mouse in an HFD group are higher than those of a WT (Wild Type) mouse in a control group; glucose tolerance tests by intraperitoneal injection discover that the tolerance of the CAD gene knock-out mouse on glucose is remarkably weakened; the integral liver appearance, liver weight, liver / weight ratio and lipid component pathological staining result of the mouse indicate that the fatty liver disease of the CAD knock-out mouse in the HFD group is remarkably severe, the lipid accumulation is remarkably increased, and these results indicate that CAD gene knock-out can remarkably deteriorate fatty liver and type-II diabetes mellitus. Regarding the effects of CAD, the CAD can be used for preparing medicaments for preventing, relieving and / or treating fatty liver and / or type-II diabetes mellitus.

The invention discloses a feed additive for preventing fatty liver of cultured fishes and a preparation method and belongs to the field of feed additives of aquaculture fish feed. The additive is prepared from compound nucleotide, S-adenosine-L-methionine, glycine and zeolite powder; the compound nucleotide is prepared from adenosine-5'-monophosphoric acid disodium salt, uridine-5'-monophosphoricacid disodium salt, cytidine-5'-monophosphate disodium salt, guanosine 5'-monophosphate disodium salt and disodium 5'-inosinate according to the mass ratio of 1 to 1 to 1 to 1 to 1. According to the additive disclosed by the invention, the adding amount in fish type high-energy feed is 0.5 to 1.5 percent, the ratio of liver weight to body weight of the cultured fishes can be remarkably reduced by15 to 20 percent and the fatty content of livers is reduced by 15 to 25 percent; meanwhile, the feed has the effect of improving the immunity of the cultured fishes and can be used for effectively preventing nutritional fatty liver diseases and secondary diseases of the fishes in aquaculture, and the feed has good popularization and application value.

The invention belongs to the technical field of animal liver perfusion for separation of liver cells and in particular relates to a liver perfusion method for separating rat liver cells and a perfusion apparatus of the method. In the method, according to a principle design of a classic two-step perfusion method, weight changes of rat livers are monitored in real time in a second step of enzyme liquid perfusion, and stop of the perfusion process is automatically controlled at the right time. The perfusion apparatus comprises a weighing platform, a perfusion system and a data processing system, wherein the perfusion system comprises a buffer solution tank, a peristaltic pump, a thermostat, a bubble trap and a puncture needle connected in sequence by virtue of infusion tubes; the weighing platform is electrically connected with the data processing system; rat livers are arranged on the weighing platform. The invention provides a perfusion apparatus capable of continuously monitoring liver weight changes in the perfusion process, and perfusion can be automatically stopped at the right time, so that viability and quantities of liver cells separated after liver perfusion are obviously improved, and the perfusion apparatus has significant substantive features.